Lexaria Bioscience (LEXX) Long-Term Deferred Tax (2020 - 2025)

Lexaria Bioscience has disclosed Long-Term Deferred Tax across 4 years of filings, most recently posting $13.4 million for Q3 2025.

• Long-Term Deferred Tax for Q3 2025 came in at $13.4 million, changed N/A year-over-year; the trailing twelve-month figure through Aug 2025 was $13.4 million (changed N/A YoY), and the FY2025 annual result was $13.4 million, changed N/A from the prior year.
• Long-Term Deferred Tax came in at $13.4 million for Q3 2025 at Lexaria Bioscience, up from $9.6 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $13.4 million in Q3 2025 to a low of $6.6 million in Q3 2021.
• The 3-year median for Long-Term Deferred Tax is $9.6 million (2023), against an average of $9.9 million.
• Peak annual rise in Long-Term Deferred Tax reached 18.01% in 2021, while the deepest fall reached 18.01% in 2021.
• Lexaria Bioscience's Long-Term Deferred Tax stood at $6.6 million in 2021, then soared by 45.29% to $9.6 million in 2023, then surged by 39.99% to $13.4 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $13.4 million (Q3 2025), $9.6 million (Q3 2023), and $6.6 million (Q3 2021), per Business Quant data.